111 Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010 36: 1185–1206. 112 Zuiga J, Torres-García D, Santos-Mendoza T, et al. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012 2012: 193923. 113 Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017 7: e012567. 114 Wang G, Xu J, Huang B, et al. Epidemiological characteristics of pulmonary tuberculosis among health-care workers in Henan, China from 2010 to 2017. BMC Infect Dis 2020 20: 484. 115 Raanan R, Zack O, Ruben M, et al. Occupational silica exposure and dose–response for related disorders— silicosis, pulmonary TB, AIDs and renal diseases: results of a 15–year Israeli aurveillance. Int J Environ Res Public Health 2022 19: 15010. 116 Ehrlich R, Akugizibwe P, Siegfried N, et al. The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. BMC Public Health 2021 21: 953. 117 National Institute for Health and Care Excellence. Tuberculosis. https://www.nice.org.uk/guidance/ng33 Date last accessed 17 July 2023. 118 Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS ONE 2011 6: e29563. 119 Ji X, Hu L, Wang Y, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. Chin Med J (Engl) 2022 135: 409–415. 120 Alemu A, Bitew ZW, Diriba G, et al. Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis. Int J Infect Dis 2022 122: 188–201. 121 Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis 2014 6: 2014026. 122 Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005 171: 1430–1435. 123 Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent tuberculosis disease: a population-level cohort study. Clin Infect Dis 2021 72: 1919–1926 Disclosures: K. Nelson reports receiving grants or contracts from the NIH, the American Lung Association and the Centers for Disease Control and Prevention, outside the submitted work. The remaining authors have nothing to disclose. https://doi.org/10.1183/2312508X.10023922 33 EPIDEMIOLOGY |R. VERSTRAETEN ET AL.